![]() Future data will continue to investigate faricimab for real-world patients with nAMD.įinancial Disclosures: Dr. It has been well-tolerated with low incidence of treatable intraocular inflammation. One case of infectious endophthalmitis was treated with intravitreal antibiotics and resolved.įaricimab has demonstrated improvement or maintenance of visual acuity for patients with nAMD, along with rapid improvement of anatomical parameters. One case of intraocular inflammation was observed after four injections of faricimab and resolved with topical steroids. After three injections of faricimab, all eyes (n = 94), previously-treated (n = 81) and treatment-naïve (n = 13) eyes demonstrated a + 3.4 letter (p = 0.03), a + 2.7 letter (p = 0.045) and a + 8.1 letter (p = 0.437) improvement in BCVA, and a - 43.4 μM (p < 0.001), a - 38.1 μM (p < 0.001) and a - 80.1 μM (p < 0.204) reduction in CST, respectively. Secondary outcome measures included treatment intervals and presence of retinal fluid.Īfter one injection of faricimab, all eyes (n = 376), previously-treated (n = 337) and treatment-naïve (n = 39) eyes demonstrated a + 1.1 letter (p = 0.035), a + 0.7 letter (p = 0.196) and a + 4.9 letter (p = 0.076) improvement in BCVA, respectively, and a - 31.3 μM (p < 0.001), a - 25.3 μM (p < 0.001) and a - 84.5 μM (p < 0.001) reduction in CST, respectively. The main outcome measures are changes in BCVA, changes in central subfield thickness (CST) and adverse events. Collected data includes background demographics, treatment history, best-corrected visual acuity (BCVA), anatomic changes, and adverse events as safety markers. Multicenter, retrospective chart review was conducted on patients treated with faricimab for nAMD from February 2022 to September 2022. Investigate real-world patients receiving faricimab for the treatment of neovascular age-related macular degeneration (nAMD).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |